This is a published notice on the Find a Tender service: <u>https://www.find-tender.service.gov.uk/Notice/034019-2024</u>

Tender Blood Extraction Platform

BRISTOL & WESTON NHS PURCHASING CONSORTIUM

F02: Contract notice Notice identifier: 2024/S 000-034019 Procurement identifier (OCID): ocds-h6vhtk-04afd3 Published 21 October 2024, 5:08pm

Section I: Contracting authority

I.1) Name and addresses

BRISTOL & WESTON NHS PURCHASING CONSORTIUM

Christopher Handcock Building

BRISTOL

BS10 5NB

Contact

Jessica Allen

Email

jessica.allen@nbt.nhs.uk

Telephone

+44 1174140797

Country

United Kingdom

Region code

UKK11 - Bristol, City of

Justification for not providing organisation identifier

Not on any register

Internet address(es)

Main address

https://www.nbt.nhs.uk/

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge, at

https://www.sap.com/products/spend-management/ariba-login.html

Additional information can be obtained from the above-mentioned address

Tenders or requests to participate must be submitted electronically via

https://www.sap.com/products/spend-management/ariba-login.html

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Blood Extraction Platform

Reference number

WS2214880748

II.1.2) Main CPV code

• 33100000 - Medical equipments

II.1.3) Type of contract

Supplies

II.1.4) Short description

This contract is for 6 years with an options 1 year extension. Full details are provided in the Invitation To Tender pack. This is provided in the SAP Ariba portal.

In 2018 NHSE commissioned Genomic Laboratory Hubs (GLHs) for the delivery of highquality, efficient, and centralised genomic services. The South West GLH is hosted at NBT, all core rare disease, cancer testing and specialised rare disease testing in cardiology, renal and neurology is provided from the Bristol Genetics laboratory (BGL).

The purpose of this notice is to alert potential suppliers to an opportunity to provide a high throughput DNA extraction platform capable of extracting DNA from venous blood where sample volumes are greater than 2ml and be able to produce a high yield of high molecular weight (>48kb) genomic DNA to BGL. The system must produce minimum DNA yields which average between 40 and 100 micrograms of DNA from 2-10ml of human blood. This is key to ensure that the platform can meet the requirements of our Facioscapulohumeral muscular dystrophy (FSHD) service for which 95% of diagnoses are made through genomic testing using Southern Blotting.

The total funding available for this capital equipment procurement is £350,000 (inclusive of VAT) however reagent and consumable costs will also be taken into consideration when assessing the Whole Life Cost of the award. Therefore, the estimated total value is inclusive of this.

II.1.5) Estimated total value

Value excluding VAT: £525,000

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.3) Place of performance

NUTS codes

• UKK - South West (England)

Main site or place of performance

North Bristol Trust

II.2.4) Description of the procurement

Additional requirements include;

- The platform should be high throughput with flexibility in batch sizes for efficient use. These should range from a single sample to maximum batch size.

- The system must allow the use of a variety of tube types in which the extracted DNA can be collected or eluted into, in particular 2ml screw-cap tubes and 2D barcoded tubes (e.g. fluidX 0.7ml tubes).

- Cross-contamination of samples during automated processing must be shown to be absent

- The system must incorporate barcode scanning and be able to record the barcode labels of both primary tubes and DNA output tubes in a log or database.

- The system must be able to use barcoding data to match the input tube with the output tube and complete elution of DNA according to this information.

- The system must be capable of automating extraction procedure to a level where 'walkaway' operation is facilitated

- The system must be capable of sampling from the primary tube starting material (blood)avoiding the need to manually aspirate from the primary sample tube

- The system must be enclosed in such a way to protect the operators.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months

72

This contract is subject to renewal

No

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options

optional 1 year extension.

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date

21 November 2024

Local time

12:00pm

IV.2.4) Languages in which tenders or requests to participate may be submitted

English

IV.2.7) Conditions for opening of tenders

Date

21 November 2024

Local time

12:30pm

Section VI. Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

North Bristol Trust

Bristol

Country

United Kingdom